Chris Schelling, Acer Therapeutics CEO

Weeks af­ter rare dis­ease drug got spurned, Ac­er re­turns to FDA for sec­ond shot

Less than a month af­ter the FDA re­ject­ed Ac­er Ther­a­peu­tics’ treat­ment for urea cy­cle dis­or­ders be­cause its con­tract pack­ag­ing man­u­fac­tur­er wasn’t ready for an in­spec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.